Immunic AG

ACTIVE

Lochhamer Schlag 21, Gräfelfing, Bayern, Germanywww.immunic-therapeutics.comSubsidiary

Part of Vital Therapies, Inc.

Clinical Trials

31 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

59.6%

Phase 3

19.2%

Phase 2

17.3%

Trial Status Distribution

Active, not recruiting

53.9%

Completed

5.8%

Not yet recruiting

5.8%

Recruiting

30.8%

Terminated

3.9%

Clinical Trials

Trials sponsored by this organization (52)

A Randomised, Placebo‑Controlled Trial to Assess Effect of IMU‑838 on QT/QTc

Phase 1

Recruiting

Jul 202620 participants

A Phase 1, drug-drug interaction trial of IMU-838 with oral contraceptives in women

Phase 1

Recruiting

Mar 202626 participants

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 (vidofludimus calcium) versus Placebo in Adults with Relapsing Multiple Sclerosis (RMS)

Phase 3

Not yet recruiting

interventional

Dec 20231,050 participants

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)

ot Applicable

Phase 1

Recruiting

interventional

Jan 20231,050 participants

A Study of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis(ENSURE-2)

Phase 3

Recruiting

interventional

May 20221,050 participants

Study to test IMU-838 in patients with progressive multiple sclerosis

Phase 1

Active, not recruiting

Apr 2022450 participants

A Study of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE 1)

Phase 3

Recruiting

interventional

Apr 20221,050 participants

Page 1 of 7

Approvals

No approval data available

News

No news articles found

Back to Organizations